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ABSTRACT
The alternation/deficiency in activation-3 (ADA3)
is an essential component of the human
p300/CBP-associated factor (PCAF) and yeast
Spt-Ada-Gcn5-acetyltransferase (SAGA) histone
acetyltransferase complexes. These complexes fa-
cilitate transactivation of target genes by associ-
ation with transcription factors and modification of
local chromatin structure. It is known that the yeast
ADA3 is required for nuclear receptor (NR)-mediated
transactivation in yeast cells; however, the role of
mammalian ADA3 in NR signaling remains elusive.
In this study, we have investigated how the human
(h) ADA3 regulates retinoic acid receptor (RAR)
a-mediated transactivation. We show that hADA3
interacts directly with RARa in a hormone-
dependent manner and this interaction contributes
to RARa transactivation. Intriguingly, this interaction
involves classical LxxLL motifs in hADA3, as
demonstrated by both ‘loss’ and ‘gain’ of function
mutations, as well as a functional coactivator
pocket of the receptor. Additionally, we show that
hADA3 associates with RARa target gene promoter
in a hormone-dependent manner and ADA3
knockdown impairs RARb2 expression. Fur-
thermore, a structural model was established to il-
lustrate an interaction network within the ADA3/
RARa complex. These results suggest that hADA3
is a bona fide transcriptional coactivator for RARa,
acting through a conserved mechanism involving
direct contacts between NR boxes and the recep-
tor’s co-activator pocket.
INTRODUCTION
Retinoic acids (RAs), the oxidized forms of vitamin A,
possess important physiological and pharmacological
actions as they determine vertebrae development,
promote cell diﬀerentiation and aﬀect cancer cell prolifer-
ation (1). The genomic actions of RAs are mediated by
RA receptors (RARs), members of the nuclear receptor
(NR) superfamily. NRs are ligand-dependent transcrip-
tion factors that control gene expression in target cells.
To date, many NRs are known as targets for therapeutic
drugs in treating various human disorders, including
metabolic diseases and cancers (2). Structurally, NRs
share a common domain organization that consists of a
variable N-terminal activation function domain (AF-1),
a central DNA-binding domain (DBD) followed by a
short hinge/D region, and a C-terminal ligand-binding
and ligand-dependent transactivation function domain
(LBD/AF-2) (3). The highly conserved DBD contains
two zinc ﬁngers and is responsible for recognition of hor-
mone responsive elements (HREs). The LBD contributes
to a dimerization interface of the receptor, in addition to
binding co-activators and corepressors.
The transcriptional activity of NRs is thought to
be regulated by a dynamic exchange of co-activators
and corepressors (4). Crystallographic studies have
revealed that ligand-binding induces a conformational
change of the LBD and causes a positional shift of the
carboxyl-terminal AF-2 helix (helix 12 or H12) (5). This
alternation changes the cofactor-binding surface, triggers
the dissociation of corepressors such as silencing mediator
for retinoid and thyroid hormone receptors (SMRT) and
N-CoR (6,7), and subsequently recruits co-activators like
p160/SRC and CBP/p300 (8). The p160 co-activator
family includes SRC1/NCoA-1 (9), TIF2/GRIP1 (10,11)
and pCIP/AIB1/RAC3/ACTR (12,13). These three
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hormone- and AF2-dependent manner and facilitate tran-
scriptional activation by NRs. In contrast to the
corepressors, co-activators contain intrinsic histone
acetyltransferase activity (HAT) and remodel chromatin
structure in an ATP-dependent manner, as well as causing
covalent modiﬁcation of histone tails (14). Both
corepressors and co-activators interact with the same
cofactor-binding pocket on the receptor through their
a-helical LxxLL or related motifs (L represents leucine,
x represents any amino acids). These LxxLL motifs are
also known as CoRNR boxes in corepressors and as NR
boxes in co-activators, respectively (15,16). In general, the
LxxLL motif adopts a short a-helical structure and docks
into a hydrophobic co-activator-binding pocket sur-
rounded by helices H3, H4, H5 and H12 of the LBD
(17). Mutational analyses of the co-activators NR boxes
have also uncovered a receptor speciﬁc code of inter-
action, suggesting that NR box-mediated diﬀerential
contacts may determine speciﬁc modes of NR action (5).
The alternation/deﬁciency in activation-3 (ADA3) is an
essential component of the human PCAF and yeast
SAGA or ADA HAT complexes. These complexes are
known to stimulate transcription by association with
DNA-binding factors and by modifying local chromatin
structure (18,19). Through direct interactions, ADA3 par-
ticipates in diverse physiological processes, and regulates
the functions of several important proteins such as the
tumor suppressor p53 (20), HPV E6 (21), several NRs
(22) and ANCO-1 (23). In particular, the yeast ADA3
(yADA3) directly interacts with hRXRa and hERa in a
ligand-dependent manner to augment their transactivation
in yeast cells (24). In contrast, other studies have reported
that the mouse ADA3 (mADA3) does not interact with
these NRs (25) and the yADA3 and hADA3 reportedly
fail to interact with hRARa (24,26). Hence, it is assumed
that the hADA3 plays an indirect role in regulating RAR’s
transcriptional activity through interaction with either
RXRs or p160 co-activators (27).
Previously, we have determined the molecular mecha-
nisms of the assembly of RXRa with corepressor and
co-activator complexes (28,29) complexes. To extend our
understanding of the mechanisms of retinoid signaling, we
have characterized the potential physical and functional
interactions between hADA3 and hRARa. Our results
suggest that hADA3 is essential for hRARa transactiva-
tion and that hADA3 interacts directly with hRARa.
A favorable structural model of the ADA3 LxxLL
motif/RARa complex is established and the underlying
molecular interactions are postulated.
MATERIALS AND METHODS
Chemicals and reagents
All-trans RA (atRA), rifampicin (Rif),
1,25-dihydroxyvitamin D3, 17b-estradiol (E2), and
3,5,30-triiodothyronine (T3) were purchased from Sigma
(St. Louis, MO, USA). The anti-ADA3 polyclonal
antibody was a generous gift from Dr Pierre Chambon
(IGBMC, Illkirch, France). The anti-Actin monoclonal
antibody was purchased from Sigma.
Plasmids
The pCMX-hRARa wild-type and E412K mutant, and
the pDR5-tk-luc reporter have been described previously
(29). The hRARa K399E, ME400/1AA, I402A, PG403/
4AA, SM405/6AA, PP407/8DT, LI409/10AA, L409A,
I410A, Q411A, ML413/4AA, M413A, L414A, E415K,
NS416/7AA, EG418/9AA and LD420/1AA mutants
were created on the pCMXHA-hRARa template using
the Quick Change Site-directed Mutagenesis kit
(Stratagene, La Jolla, CA, USA). The series of GAL4
DBD-hRARa H12 mutants for expression in yeast cells
were constructed in the pGBT9 vector at NcoI and
BamHI cloning sites. The pACT-hADA3,
pACT-hADA2a, pACT-hADA2b, pGBT-ANCO-1C
(aa 2369–2663) and pGEX-hADA3 are as described pre-
viously (23). The NR box motifs of hADA3 were mutated
as indicated and the primer sequences (50 to 30) for each
NR box mutants are: mNR1, CTG CAG CTG GAG
GCG GAG ACC GCG GCG TCT TCT GCC; mNR2,
AGG TCC GCA CAG CTG AGG AGG CAG CGA
AGC CCC CA; mNR3, GAC ACT AAA GAT GCG
GCT GCC GCG GCG AAG AAG TCT GAG; mNR4,
CTG ACG CAG CGC GCC GCG CAG GCC GCG
GCG GAG GAA AAT; mNR5, GAG CGT GAG
AGC GCC GCG AAG GCG GCG GAT GGG TAG;
V237L, GGA CAC TAA AGA TCT GGA TGC CCT
GCT GAA G; V269L, CCT GCA GGC CCT GCT
GGA GGA AAA TAT TAT TTC C; I426L, GGA
GCG TGA GAG CCT CCT GAA GCT GCT GGA
TGG. All constructs have been conﬁrmed by enzyme di-
gestion and DNA sequencing with additional information
available upon request.
Yeast two-hybrid assay
Yeast Y190 cells were co-transformed with the GAL4
DBD fusion plasmids (pAS-hRARa, pAS-hRARg,
pGBT-hRARa, pAS-hTRa, pAS-hERa, pGBT-VDR or
pGBT-PXR) and the GAL4 AD fusion plasmids
(pACT2 vector or pACT-hADA3), together with 4mgo f
single-strand salmon sperm DNA according to manufac-
turer’s instructions (Clontech, Palo Alto, CA, USA).
Yeast transformants were spread onto synthetic
complete plates lacking tryptophan and leucine (SC-
Trp-Leu) and incubated for 3 days at 30 C. Colonies
were picked and grown in selection media for additional
24h at 30 C. Aliquots of 100ml from each sample were
taken and added to fresh selection media. For each
sample, one aliquot received cognate ligand (atRA, E2
or T3) and the other aliquot received vehicle control
(DMSO). After 12h, yeast cells were harvested and resus-
pended in Z buﬀer (60mM Na2HPO4, 40mM NaH2PO4,
10mM KCl, 1mM MgSO4, pH 7.0) and permeated with
0.05% SDS. An aliquot of 100ml Z buﬀer containing
4mg/ml ONPG (o-nitrophenyl b-D-galactopyronoside)
was added and incubated at 30 C until the appearance
of yellowish color. The reactions were stopped by
adding 100mlo f1 MN a 2CO3 and the incubation time
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OD420 values of the supernatants were measured.
The b-galactosidase unit was calculated according to the
OD420 value, cell numbers and incubation time.
GST pull-down assay
GST and GST-hADA3 fusion proteins were expressed in
Escherichiacoli BL-21 cells and puriﬁed by glutathione
agarose beads (GE Healthcare Biosciences, Uppsala,
Sweden). Human RARa,E R a and AR were in vitro
translated and radiolabeled with [
35S]-methionine using
the TNT Quick Coupled Transcription/Translation
System (Promega, Madison, WI, USA). For the GST
pull-down experiment, 5mg of bead-conjugated fusion
protein was incubated with 4mlo fin vitro translated
35S-labeled protein with moderate shaking at 4 C over-
night as previously described (28). Bound proteins were
washed three times with fresh binding buﬀer containing
0.1% NP40, and beads were collected and subjected to
SDS–PAGE electrophoresis. Gels were then stained with
Coomassie Blue, dried and detected by autoradiography.
Cell culture and transient transfection reporter assay
HEK293 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine
serum. One day prior to transfection, cells were seeded
in 12-well plates at 50000 cells per well in phenol red
free Dulbecco’s modiﬁed Eagle’s medium supplemented
with 10% charcoal resin-stripped fetal bovine serum.
Transfection was performed using standard calcium/phos-
phate method as described (29). After transfection, cells
were washed with phosphate-buﬀered saline and re-fed
with fresh medium containing vehicle alone or vehicle
plus 50nM atRA and incubated for an additional 48h.
Cells were then harvested and analyzed for luciferase
and b-galactosidase activities.
RNA interference
The eﬀect of hADA3 short hairpin RNA (shRNA) on
RARa transcriptional activity was analyzed in HEK293
cells. The hADA3, PIASy and a control shRNAs were
expressed from the pLL3.7 lentiviral vector (30). The
sequence for the hADA3 shRNA is 50-GAT GAG GCT
GAG CAT TAC A-30 starting at nucleotide 543/amino
acid 181 of hADA3 (NM_006354). The sequence for
PIASy shRNA is 50-GCT CTA CGG AAA GTA CTT
A-30 starting at nucleotide 330/amino acid 110 of the
human PIASy (BC029874). The control shRNA
sequence is 50-GGT CCG GCT CCC CCA AAT G-30,
which has no homologous sequences in the vertebrate
transcriptome. After 24h of transfection with the
shRNA expression plasmid, the HEK293 cells containing
transiently transfected hRARa and the luciferase reporter
gene were treated with 50nM atRA for 12h and analyzed
for luciferase activity.
Generation of ADA3 stable knockdown cells
Recombinant lentiviruses were produced by
co-transfecting HEK 293T cells with the lentivirus
expression plasmid and lentiviral packaging constructs
pLP1, pLP2 and the pLP/VSV-G plasmids using
Lipofectamine 2000 (Invitrogen). Infectious lentiviruses
were harvested at 48h post-transfection from the culture
supernatants, centrifuged to eliminate cell debris and then
ﬁltered through 0.22-mm ﬁlters. For transducing lentiviral
constructs, 50% conﬂuent MCF7 cells were fed with virus
containing medium for 2 days to generate 40% infected
MCF7 cells by visualizing GFP expression. The top 20%
of GFP positive cells were subsequently collected using
ﬂuorescence-activated cell sorting analysis to retrieve the
highest GFP expressed cells. The lentivirus-infected
MCF-7 cells with siCTRL and siADA3 were grown in
serum free DMEM for overnight and treated with or
without 2mM atRA for 3h. Total RNA was extracted
using Trizol reagents (Invitrogen), and 2mg RNA was
reverse transcribed using Superscript II reverse transcript-
ase (Invitrogen) with random oligo(dT) primers. RT
products were ampliﬁed by PCR using the following
primer pairs: for the RARb2 coding sequence (421bp),
forward, 50-GGA ACG CAT TCG GAA GGC TT-30
and reverse, 50-AGC ACT TCT GGA GTC GAC
AG-30; for the hADA3 coding sequence, forward,
50-TGT GCC GCA TAC TAA GTC C-30 and reverse,
50-GCT TCA GGA TGC TCT CAC GCT-30; for the
control GAPDH coding sequence (212bp), forward,
50-GTG GAT ATT GTT GCC ATC A-30 and reverse,
50-GAC TCC ACG ACG TAC TCA-30. PCR products
were then separated by electrophoresis on 1.5% agarose
gel and visualized by ethidium bromide staining.
Chromatin immunoprecipitation assay
HEK293 cells were transiently transfected with
FLAG-tagged hRARa and HA-tagged hADA3 according
to the manufacturer’s instruction (Lipofectamin 2000,
Invitrogen). After treated with 2mM atRA for 3h, cells
were incubated with 1% formaldehyde in culture media
for 10min at 37 C. The formaldehyde cross-linked cells
were washed twice with ice-cold PBS and lysed in SDS
buﬀer [1% SDS, 10mM EDTA, 50mM Tris–HCl, pH
8.1 and protease inhibitor cocktail (Roche)]. Nuclei were
collected, resuspended in lysis buﬀer and sonicated
10 times with 15-s pulses on ice. Supernatant were then
diluted in 10-fold Dilution buﬀer (0.01% SDS, 1.1%
Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, pH
8.1, 16.7mM NaCl) and pre-cleared with 80ml of salmon
sperm DNA-protein G-agarose (Upstate) for 2h at 4 C.
The sheared DNA mixture was subjected to overnight
incubation with 1mg of anti-FLAG antibody (F3165,
Sigma), anti-HA antibody (1815015, Roche), anti-RNA
polymerase II antibody (05-623B, Upstate) or an equal
amount of normal mouse immunoglobulin G (Santa
Cruz Biotechnology) at 4 C. Immunoprecipitation was
performed using protein G agarose for 1h at 4 C. The
protein/DNA cross-links were reversed by heating at
65 C for 6h, and then the DNA were extracted using
QIAquick PCR puriﬁcation kit (Qiagen). For PCR
reaction, 3ml from a 40ml DNA preparation was used
for ampliﬁcations. The DNA product was analyzed
using a primer set against RARb2 promoter, 50-AAG
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CCC GAC GGT G-30 (GenBank accession number
AF275948). The 228bp RARb2-promoter were visualized
on a 1.5% agarose gel.
Molecular modeling
The initial model for RARa/hADA3 complex was con-
structed based on the crystal structure of the RARb/
RXRa complex with an LxxLL peptide from the
TRAP220 co-activator (PDB: IXDK) (31). Due to the
high sequence identity shared between RARa and
RARb ( 88%), the distinct residues on RARb were
directly mutated to the respective residues on hRARa
and the coordinates of the NR box 4 peptide of hADA3
were built from those of the TRAP220 peptide. The re-
sulting models were subjected to energy minimization for
2500 steps of steepest descent geometry optimization
followed by 2500 steps of conjugate gradient optimization
with RARa LBD held ﬁxed, except for the residues
making contact with the ADA3 peptide. The energy
minimized structural model of the RARa/ADA3
complex was then utilized as the initial structure for
Molecular Dynamics (MD) simulation. The model was
ﬁrst solvated by explicit water molecules, followed by
5000 steps energy minimization. The temperature of the
system was heated gradually from 100 to 300K for 200 ps
and kept constant throughout the later simulation.
Furthermore, a 500 ps equilibration step was conducted
at 300K and 1 atmosphere constant pressure to adjust the
solvent density. Finally, another 2ns MD simulation was
run for data collection with snapshots obtained every 2 ps.
RESULTS
Human ADA3 enhances the transcriptional activity of
hRARa in mammalian cells
To investigate the role of hADA3 in RAR signaling, we
measured the eﬀects of hADA3 overexpression and
silencing on hRARa-mediated transcriptional activation,
using a transient transfection reporter assay in the human
embryonic kidney HEK293 cells. As shown in Figure 1A,
ectopically expressed hADA3 enhanced the activation of
RARa-driven transcription in the presence of atRA in an
ADA3 concentration-dependent manner, suggesting that
hADA3 may function as a co-activator for RARa.
To determine whether endogenous hADA3 contributes
to the RARa-mediated transcriptional activation, we
knocked down the endogenous ADA3 in HEK293 cells
by shRNA using a lentivirus vector (Figure 1B, inset).
While the control shRNAs had no eﬀect, silencing of
hADA3 signiﬁcantly reduced RARa-mediated transacti-
vation (Figure 1B). Therefore, both the endogenous and
ectopically expressed hADA3 are involved in enhancing
RARa-mediated transcriptional activation. Additionally,
we examined the eﬀect of ADA3 knockdown on the
RARa downstream gene regulation. ADA3 knockdown
cells were created using lentivirus-based siRNA system
in MCF7 cells. As shown in Figure 1C, the expression
of RARb2, upon its induction by atRA, was much
lower in the ADA3 knockdown cells as compared with
control cells. This result suggests that hADA3 acts as an
RARa co-activator regulating its target gene expression.
ADA3 interacts directly with liganded RARa
Next, we tested if hADA3 interacts directly with RARa.
Yeast Y190 cells expressing both the GAL4 DBD-hRARa
and GAL4 AD-hADA3 fusions proliferated well on
a -Trp-Leu-His+3AT (3-aminotriazole) plate in the
presence of atRA (Figure 2A). In contrast, cells without
the hRARa or hADA3 fusions were unable to grow under
the same conditions regardless of atRA. As controls, all
transformants proliferated equally well on -Trp-Leu plates
(left panels). This ADA3/RARa interaction was con-
ﬁrmed by using diﬀerent GAL4 DBD-RAR constructs
(Figure 2B), suggesting that hADA3 interacts speciﬁcally
with RARs in a ligand-dependent manner.
We next examined ADA family proteins, including
hADA3, hADA2a and hADA2b, for their interaction po-
tentials with various NRs. Interestingly, only hADA3 was
able to interact with these NRs in the presence of cognate
ligands, while hADA2a/b show little interaction regardless
of ligands (Figure 2C). These results suggest hADA3
subunit as a potential mediator in the recruitment of
PCAF/ADA complex to ligand-activated NRs. The inter-
actions between hADA3 and NRs were further
demonstrated in vitro using GST pull-down assays
(Figure 2D), where hRARa and hERa showed speciﬁc
ligand-enhanced interactions with hADA3 while hAR ex-
hibited a ligand-independent interaction. These results
suggest that hADA3 interacts directly with several NRs
in a hormone-dependent manner in vivo and in vitro.
ADA3 binds to the co-activator pocket of RARa
The H12 helix at the carboxyl-terminal end of NR plays a
critical role in the formation of a ligand-induced
co-activator-binding pocket (17). To determine if the
co-activator pocket is responsible for ADA3 binding, we
systematically mutated each amino acid spanning the H12
helix of hRARa (Figure 3A). These RARa mutants were
labeled with [
35S]-methionine and tested by GST
pull-down assay for interaction with GST-hADA3 in the
presence of atRA in vitro. As shown in Figure 3B, SM405/
6AA, PP407/8DT, LI409/10AA, L409A, I410A, E412K
and ML413/4AA mutations all interrupted RARa inter-
action with hADA3, suggesting that H12 helix is essential
for ADA3 binding. In contrast, the Q411A mutant within
the H12 helix did not aﬀect the interaction, suggesting that
the side chain of Q411 is not critical for ADA3
interaction.
To compare the RARa interaction proﬁles between
ADA3 and p160 co-activator, yeast two-hybrid assays
were carried out to determine the interaction of RARa
H12 mutants with ADA3 and RAC3 (Figure 3C).
We found that the ligand-induced interaction patterns of
hRARa and hADA3 in yeast cells were consistent with
that of the GST pull-down assay. Moreover, the hRARa
interacting proﬁles with hADA3 and RAC3 were similar
(Figure 3C). As a control, except for the PG403/4AA
mutant, none of these GAL4 DBD-fused hRARa
mutants displayed signiﬁcant background activation,
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and similar interacting proﬁle to RAC3 suggest that
hADA3 interacts with the co-activator-binding pocket of
hRARa.
ADA3 interaction mutants of RARa display impaired
transcriptional activity
To strengthen the idea that ADA3 is a transcriptional
co-activator for RARa through a mechanism involving
direct protein–protein contact, we assessed the transcrip-
tional potentials of the RARa H12 mutants by transient
transfection reporter assay. Since endogenous ADA3 may
function as a co-activator for RARa, this experiment was
conducted in the absence of ADA3 overexpression.
As shown in Figure 4, the RARa H12 mutants that are
defective in ADA3 interaction also displayed impaired
transactivation function. These data suggest that ADA3
interaction may contribute to RARa transcriptional
activity. Interestingly, most of these ADA3 interaction
mutants also display dominant-negative eﬀects as they
suppressed the reporter gene expression below control
level, possibly due to sequestration of endogenous cofac-
tors. Although the contribution of other transcriptional
co-activators, such as the p160 proteins, cannot be
undermined, these results support the idea of ADA3 as
a co-activator for RARa.
Figure 1. The human ADA3 enhances transcriptional activity of RARa in mammalian cells. (A) Ectopic overexpression of human ADA3 enhances
transcriptional activation mediated by hRARa. HEK293 cells were cotransfected with pCMX-hRARa, pDR5-tk-Luc reporter and indicated amounts
(inmg) of pCMX-hADA3. Cells were incubated in the absence (white bars) or presence (black bars) of 50nM atRA. The relative luciferase activities
were determined from three independent samples after normalization to the internal b-galactosidase control. (B) Endogenous human ADA3 con-
tributes to RARa-mediated transcriptional activation. HEK293 cells were cotransfected with pCMX-hRARa and pDR5-tk-Luc reporter plus pLL3.7
shRNA expression vector without an insert ( ), or with the control (Ctrl), hADA3 or PIASy targeting shRNA. The relative luciferase activities were
determined from three independent samples after normalization to the internal b-galactosidase control. The small inset in the graph is a western blot
showing the reduction of ADA3 by the pLL3.7-hADA3 shRNA, which has no eﬀect on the expression of endogenous b-actin. (C) Expression of
RARb2 is impaired in ADA3 knockdown cells. Total RNA was extracted from each of the control (siCTRL) or siADA3-infected stable clones
without or with atRA treatment and the RNA was subjected to RT-PCR using primers speciﬁc for RARb2 or ADA3 coding sequence. GAPDH was
used as an internal control.
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interaction with RARa
Several NR co-activators, including the p160 and
DRIP220, utilize highly conserved LxxLL motifs to
interact with the co-activator-binding pocket of the
receptor. Previously, two putative LxxLL motifs were
identiﬁed in the mouse ADA3, although they were
excluded from mediating interaction with NRs (25). As
shown in Figure 5A, we have located ﬁve putative
LxxLL consensus sequences in the hADA3 sequence.
We tested whether these putative LxxLL motifs are
involved in interaction with RARa. Site-directed muta-
tions of conserved hydrophobic amino acids within each
motif were created and tested for interaction with liganded
RARa in a yeast two-hybrid assay. Intriguingly, alter-
ations of NR box 3 (mNR3), 4 (mNR4) and 5 (mNR5)
showed diminished interaction with RARa in the presence
of atRA (Figure 5B). In contrast, alterations in NR boxes
1 (mNR1) and 2 (mNR2) had little eﬀect. As a control
(Figure 5C), none of these NR box mutations of ADA3
aﬀected its interaction with ANCO-1 (32). These results
suggest that hADA3 may utilize speciﬁc LxxLL motifs for
interaction with the co-activator pocket of RARa.
Additionally, the eﬀect of NR box mutation on the
hRARa co-activator function of ADA3 was investigated
by transient transfection reporter gene assay. Consistently,
Figure 2. ADA3 binds to RARa in a ligand-dependent manner. (A) Yeast two-hybrid assay showing ligand-dependent RARa-ADA3 interaction.
Full-length hRARa was expressed as GAL4 DBD fusion from pAS1 vector, while full-length hADA3 as GAL4 AD fusion from pACT2 vector.
Yeast Y190 cells harboring the indicated plasmids were spotted onto SC-Trp-Leu or SC-Trp-Leu-His+3AT (20mM) plates, in the absence (solvent)
or presence of atRA (100nM). The numbers of cells spotted are shown at the bottom. (B) Interaction of hADA3 with various RAR plasmids in yeast
two-hybrid assay. Yeast transformants containing indicated combinations of the speciﬁed RAR plasmid and pACT-hADA3 were grown on
SC-Trp-Leu media supplemented without ( ) or with (+) 1mM of atRA. (C) Ligand-dependent interactions of ADA3 with various NRs in yeast
two-hybrid assay. Y190 cells were transformed with the GAL4 DBD fusion of various indicated NRs together with the indicated GAL4 AD fusion
of hADA3, hADA2a or hADA2b. Transformants were grown in SC-Trp-Leu selection media in the presence or absence of cognate ligand (10nM E2
for ERa, 10nM atRA for RARa, 10nM T3 for TRb, 10nM vitamin D3 for VDR and 10mM rifampicin for PXR). (D) Interactions of hADA3 with
NRs in vitro by GST pull-down assay. Puriﬁed GST proteins were incubated with [
35S]-labeled hRARa, hERa or hAR without or with ligands (1mM
atRA for hRARa, 100nM E2 for hERa and 100nM DHT for hAR).
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amino acids for individual mutations are as indicated at the mutated residues. (B) A GST pull-down assay showing interactions of GST-hADA3 with
[
35S]-hRARa and its mutants. Approximately 20% of the labeled proteins used in the pull-down reaction are shown in the input panel. The
pull-down panel shows the amount of labeled RARa that interacted with GST-hADA3 or GST alone (ﬁrst lane) in the presence of 1mMo f
atRA. (C) Comparison of the interactions of RARa H12 mutants between hADA3 and RAC3 in yeast two-hybrid assay. Yeast Y190 cells were
co-transformed with each indicated pAS-hRARa construct shown at bottom together with pACT-hADA3, pACT-RAC3 or pACT2 empty vector.
The transformed cells were grown in SC-Trp-Leu media containing either solvent (open bars) or 100nM of atRA (solid bars) for 36h. The
b-galactosidase units reﬂect interactions between various hRARa constructs with empty vector, RAC3 or ADA3, respectively.
Figure 4. ADA3 interaction deﬁciency mutants of RARa display impaired transcriptional function in mammalian cells. The transcriptional activities
of the hRARa H12 mutants shown in Figure 3A were determined by transient transfection reporter assay in HEK293 cells. Each of the indicated
pCMX-hRARa constructs was cotransfected with the pDR5-tk-Luc reporter and the b-galactosidase control plasmid. Transfected cells were treated
with either solvent (white bars) or 50nM atRA (black bars). The relative luciferase activities were determined from three independent samples after
normalization to the internal b-galactosidase control.
Nucleic Acids Research, 2010,Vol.38, No. 16 5297NR boxes 3, 4 and 5 mutants failed to enhance transacti-
vation of hRARa (Figure 5D). These results suggest that
the three NR boxes of hADA3 are involved in interaction
and coactivation with hRARa.
‘Gain-of-function’ mutants and association of ADA3 with
RAR target genes
The three putative NR boxes of ADA3 that are involved
in interaction with RARa are atypical LxxLL motifs that
may not be optimal for binding NRs. Therefore, we
mutated the NR box 3 sequence from VDALL to
LDALL (creating the V237L mutant), the box
4 LQALV to LAQLL (creating the V269L mutant) and
the box 5 ILKLL to LLKLL (creating the I426L mutant).
These potential ‘gain-of-function’ mutations were tested
for interaction with hRARa in yeast two-hybrid assay.
In this experiment, we found that all three mutations
enhanced the interaction of ADA3 with liganded
hRARa, although the eﬀect of NR box 4 mutation was
less signiﬁcant (Figure 6A). Together with the
‘loss-of-function’ mutants, these ‘gain-of-function’
mutants strongly indicate that ADA3 indeed interacts
with hRARa via a mechanism involving NR boxes.
Furthermore, to determine if hADA3 could be recruited
to RAR target genes, chromatin immunoprecipitation
(ChIP) assay was performed. We transfected
FLAG-tagged hRARa and HA-tagged hADA3 into
both HEK293 and HeLa cells and conducted ChIP
assays using monoclonal anti-FLAG and -HA antibodies
on the nature hRARb2 target promoter. In this experi-
ment, the hRARb2 promoter region that contains RAR
responsive element was immunoprecipitated as expected
with the anti-FLAG antibody, but not with the control
IgG (Figure 6B). The same hRARb2 promoter region
was also immunoprecipitated with anti-HA antibody,
but this occurred only in the presence of HA-hADA3
co-transfection and atRA treatment. Similar results were
obtained in both HEK293 and HeLa cells. These data
strongly suggest that ADA3 indeed can associate with
Figure 5. Three NR boxes in ADA3 are required for RARa interaction. (A) Amino acid alignment of the ﬁve putative hADA3 NR boxes and their
corresponding mutants. Relative positions of individual NR boxes are marked in the hADA3 schematic structure on top. The amino acid positions
relative to the LxxLL core motif are shown on top of the peptide sequence. (B) Yeast two-hybrid interactions of pACT-hRARa with pGBT-hADA3
wild-type or NR box mutants. Vector indicates blank pGBT9 vector. Cells were treated with 50nM atRA for 24h before b-galactosidase assay.
Mutations of NR boxes 1 and 2 had no eﬀect on RARa interaction, while mutations of NR boxes 3, 4 and 5 abolished the interaction. (C) Yeast
two-hybrid interactions of pACT-ANCO-1C with pGBT-hADA3 wild-type and NR box mutants. None of the ADA3 NR box mutations aﬀected the
interaction between hADA3 with ANCO-1. (D) ADA3 NR boxes 3, 4 and 5 mutations abolished the coactivation function of hADA3 on hRARa.
HEK293 cells were cotransfected with pCMX-hRARa along with indicated pCMX-hADA3 constructs. Transfected cells were treated with 100nM
atRA or solvent as control. Relative luciferase activity was determined from three independent experiments after normalization with co-transfected
b-galactosidase internal control.
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dependent manner.
A structural model of the ADA3/RARa complex
To corroborate on the ﬁndings that the LxxLL motifs
of ADA3 and the co-activator pocket of RARa are
involved in their interaction, we employed a molecular
modeling technique to deduce the most favorable struc-
tural model of the hADA3 NR box 4 peptide complexed
with the hRARa LBD. An existing crystal structure of
the hRARb/TRAP220 complex (31) was used as a mo-
lecular template for building the hRARa/ADA3 NR
box 4 peptide structural model. The ADA3 NR box
4 (QRLLQALVEE) was chosen because it is essential
for interaction with RARa and bears the highest similarity
(70%) to the TRAP220 NR box 2 (RHKILHRLLQEGS)
used in the crystal study (31). The resultant model was
further reﬁned using MD and energy minimization. The
sequence of the NR box 4 was modeled as a short
two-turn a-helix. The average structure derived from
a 2ns MD simulation indicates that the ADA3 peptide
mimicked the observed binding mode of the LxxLL
motif to other NR LBDs, and interacted with the RARa
LBD through a hydrophobic groove formed by helices 3,
4, 5 and 12 (Figure 7A). The proper position of the peptide
was locked by two conserved charge clamp residues,
Lys244 and Glu412 positioned at opposite ends of the
cleft via their electrostatic interactions with backbone
atoms on the ends of the motif helix. A complex
network of hydrogen bonds is formed between the
amino-terminal residues of the peptide and the surround-
ing residues on the receptor (Figure 6B). In addition to the
classical charge clamp interaction between Glu412 and the
amide nitrogen atom of Leu-1, two additional electrostatic
interactions are formed: one between Lys262 and Gln-3
and another between Asn416 and Arg-2. These two elec-
trostatic interactions may explain the observed diﬀerential
inﬂuence of mutated NR boxes and their interactions with
hRARa (Figure 5). This hydrogen bond network can only
form in NR boxes 3, 4 and 5, which augments the van der
Waals contacts at the core hydrophobic interface and
helps stabilize the protein–peptide complex. However,
these interactions are missing from NR boxes 1 and 2
due to the presence of hydrophobic residues at positions
-2 and -3, respectively. Compared with the binding of the
LxxLL motif from TRAP220 to hRARb, the helix formed
by ADA3 NR box 4 is shifted toward H12 by  1.7A ˚
(Figure 6C and D). Side chains of several residues
undergo conformational changes upon binding of the
ADA3 peptide. The carboxyl group of Glu412 is rotated
 180 degrees around the CB–CA bond in order to accom-
modate the shift of the ADA3 peptide toward H12. In this
binding mode, residues of Leu+1, Leu+4 and Val+5 of the
ADA3 peptide comprise the core hydrophobic interface
with the corresponding hydrophobic groove of the
RARa co-activator pocket. Their predicted interacting
residues on the receptor are listed in Table 1.
DISCUSSION
In this study, we have determined the role of human
ADA3 in RARa-mediated transcriptional activation and
investigated the underlying molecular mechanisms. We
show that hADA3 interacts directly with hRARa and
enhances its transactivation function. The interaction
between ADA3 and RARa is ligand-dependent. RARa
interacts speciﬁcally with ADA3 but not other ADA
subunits, while ADA3 may interact with other NRs.
Figure 6. (A) ‘Gain-of-function’ mutations of ADA3 NR boxes enhance interaction with RARa. We mutated the ADA3 NR Box 3 VDALL to
LDALL (V237L), Box 4 LQALV to LQALL (V269L) and Box 5 ILKLL to LLKLL (I426L). The mutations were generated on the pACT-ADA3
construct and tested for interaction with pGBT9-RARa in yeast two-hybrid assay. The pGBT9, pACT2 ( ) vectors and the pACT-ADA3 wild-type
(WT) were used as controls. The transformed colonies were grown in SC-Trp-Leu media containing either solvent (open bars) or 100nM of atRA
(solid bars) for 36h and b-galactosidase activities were determined from three independent cultures. (B) ADA3 associates with RARb2 promoter in a
hormone-dependent manner. Transiently transfected HEK293 cells were serum-starved and then stimulated with or without 2mM atRA for 3h. The
cells were subjected to in vivo ChIP assay. The FLAG, HA and RNA polymerase II antibodies were used in the immunoprecipitation. Mouse IgG
was used as a negative control, whereas input chromatin was used as loading control for the PCR reactions.
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helix (H12) of RARa co-activator pocket are identiﬁed as
essential for the interaction with ADA3, as well as for the
transactivation function of RARa. Furthermore, three
putative LxxLL NR boxes of ADA3 are found to be
critical for interaction with liganded RARa, and ADA3
is capable of associating with RAR target gene promoter
in a hormone-dependent manner. We propose a structural
model of the ADA3 NR box 4/RARa LBD complex to
illustrate the mode of interactions. These data suggest that
hADA3 is involved in RARa-mediated transactivation,
Figure 7. A structural model of the ADA3 NR box 4/RARa LBD complex. (A) An overview of the RARa-ADA3 NR box 4 complex. The RARa
LBD is shown as blue ribbons except helix 12 is colored in red. The peptide from ADA3 NR box 4 is shown in yellow. (B) Hydrogen-bond
interaction map around the N-terminal of the ADA3 NR box 4 peptide. The green dashed lines represent hydrogen bonds. The three N-terminal
residues from ADA3 peptide Leu-1, Arg-2 and Gln-3, along with the Lys262, Glu412 and Asn416 residues from RARa, are shown as indicated. (C,
D) Structural comparison between hRARb/TRAP220 and hRARa/ADA3 complexes. Helices 3, 4, 5 and 12 are displayed as blue coils and
co-activator motifs are colored in yellow. Residues on the receptor interacting with peptides are depicted in stick representation and colored by
atom-type (carbon: grey; nitrogen: blue; oxygen: red). The residues from peptides are colored in yellow and, for clarity, only residues making
signiﬁcant interactions with the LBD are shown. (C) Structure of the RARb/TRAP220 NR box 2 complex. (D) Structure of the RARa/ADA3 NR
box 4 complex.
Table 1. The hRARa residues predicted to make contacts with the
core hydrophobic residues of hADA3 NR box 4
Helix Residues
Helix 3 Ile237, Val240, Ala 243, Lys244
Helix 4 Phe249
Helix 5 Ile254, Gln257, Ile258, Leu261, Lys262
Helix 12 Leu409, Glu412, Met413
The hRARa residues are listed according to their relative locations
within indicated helices of hRARa LBD
5300 Nucleic Acids Research, 2010,Vol.38, No. 16likely through a mechanism of direct physical interactions
between the NR boxes of ADA3 and the co-activator
pocket of liganded RARa.
The involvement of ADA3 in NR signaling was ﬁrst
demonstrated in Saccharomyces cerevisiae when yeast
ADA3 was isolated as an RXRa-interacting protein
(24). The yeast ADA adaptor complex is also important
for transcriptional activation by GR (33,34) and TR (35),
where the yeast ADA2 seems to play a more important
role. The yeast ADA3 is thought to mediate transactiva-
tion by RXRa and ERa in yeast cells through direct
physical interaction and recruitment of the SAGA
complex (24). In that study, yeast ADA3 was shown to
interact in a ligand-dependent manner with RXRa,T R a
and ERa, but not with RARa. Surprisingly, the same
group reported that mouse ADA3 does not interact with
NRs, even though it contains potential LxxLL motifs (25).
Inconsistent data were reported regarding the roles of
human and mouse ADA3 in terms of their interactions
and function with human ERa/b and RXRa and
hRARa in mammalian cells (22,26). Interestingly, yeast
ADA3 was implicated in mediating RARa transactivation
through interaction with the p160 co-activator RAC3/
AIB1 and recruitment of GCN5 co-activator complex
(27). Our current results demonstrate a strong
ligand-dependent direct interaction between hADA3 and
RARa in vivo and in vitro. We show that human ADA3,
but not ADA2a or b, is capable of interaction with several
NRs including ERa,T R b, VDR, PXR and AR. This is
consistent in part with prior reports supporting a direct
role of hADA3 in ER signaling (22,26). However, it is
noted that ADA2, instead of ADA3, was previously
implicated in TRb signaling (35), although our current
data suggest that TRb interacts with hADA3 but not
ADA2a or 2b (Figure 2C). To our surprise, ADA3
seems to bind to RAR subtypes with diﬀerent aﬃnity.
In particular, RARg shows a 3-fold better interaction
with ADA3 as compared to RARa (Figure 2B). We
reason that the oloop in the RARg, which is absent in
RARa and RARb, might facilitate the conformational
change of the RAR/ADA3 interaction. Since RARa and
RARb have been shown to be associated with the devel-
opment of acute promyelocytic leukemia and squamous
cell cancers, whereas RARg is associated with retinoid
eﬀects on mucocutaneous tissues and bone, our results
suggest that ADA3 may be involved in multiple physio-
logical eﬀects mediated by diﬀerent subtypes of RARs.
While this study focuses on dissecting the molecular inter-
action between ADA3 and RARa, the attribution of RAR
target gene expression to diﬀerent co-activators has been
an important, yet challenging topic, especially due to the
existence of overlapping co-activators, and the fact that
cell is able to compensate the loss of a particular
co-activator. This is exempliﬁed in our ADA3 knockdown
experiment where RAR reporter gene expression was
aﬀected but not abolished (Figure 1B).
To corroborate on the role of human ADA3 in RARa
signaling, we have investigated the molecular basis of their
interactions. Several co-activators, including the p160
proteins, are known to utilize a simple LxxLL NR box
for interaction with a structurally conserved co-activator
pocket located on the surface of a receptor LBD
(12,29,36,37). The co-activator pocket is formed by
helices 3, 4, 5 and 12 in response to ligand-induced con-
formational change, with helix 12 serving as a dynamic lip
that closes up upon ligand binding (28,38). Our data dem-
onstrate that the co-activator pocket of RARa is indeed
required for ADA3 binding. In addition, we have
identiﬁed three potential LxxLL motifs in hADA3,
whose disruption clearly abolished the interaction
between ADA3 and RARa (Figure 5). Importantly,
‘gain-of-function’ mutations of these NR boxes that
optimize the NR-binding potentials of the LxxLL motif
enhanced interaction with RARa (Figure 6A). The fact
that the optimization of NR box 4 consensus sequence
has the least eﬀect on enhancing interaction with RARa
is consistent with the idea that this motif is nearly optimal
in interaction with RARa as demonstrated by molecular
modeling (Figure 7). Whether these NR boxes are essen-
tial for interactions with other NRs, and the relative im-
portance and the stoichiometry of these motifs, remain to
be determined. The reason that a single NR box mutation
in ADA3 abrogated interaction with RAR may be multi-
faceted. One plausible explanation is that all three NR
boxes are involved in the interaction, while each of them
is required for the formation of a stable complex in vivo.
Thus, mutation in a single NR box would result in the
destabilization of the ADA3/RAR complex.
Given that ADA3 is a key subunit of PCAF
co-activator complexes, it is reasonable to speculate that
ADA3 may act as a molecular bridge to mediate the re-
cruitment of co-activator complexes to ligand-activated
receptors. Our data show that not only the transcriptional
activity of RARa was enhanced by overexpression of
ADA3, silencing of endogenous ADA3 also diminished
reporter gene expression (Figure 1). Therefore, we
suggest that ADA3 may indeed function as a transcrip-
tional co-activator for RARa. We further speculate that
ADA3 may play a role in bringing its associated-co-
activator complexes to other NRs. Nonetheless, there
are likely receptor and receptor-subtype selectivity for
ADA3, because its interaction with AR was independent
of ligand and a better interaction with RARg subtype was
observed. Despite the positive epigenetic regulation of
gene transcription, ADA3 also directly binds and acetyl-
ates P53, reducing Mdm2-mediated ubiquitination of P53
and subsequently stabilizing p53 expression (39). In this
regard, ADA3 may also function as an RAR
acetyltransferase and aﬀect its protein turnover rate.
Various possibilities warrant detailed study and will be
addressed in future work.
The co-activator binding characteristics of RARa
between ADA3 and RAC3 were analyzed and compared
using a series of systematic helix 12 mutations in RARa
(Figure 3). Intriguingly, the interacting pattern is highly
related to RARa transactivation capability (Figure 4),
suggesting that RARa activity is controlled by these co-
factors. Additionally, the lack of ADA3 or RAC3 binding
seems to correlate with a dominant negative function of
RARa, possibly due to sequestration of endogenous co-
factors such as RXR. This observation is consistent with a
prior ﬁnding where disrupting TRb and SRC1 interaction
Nucleic Acids Research, 2010,Vol.38, No. 16 5301resulted in a dominant negative regulation in TRb (40).
Similarly, the transcriptional regulation of Hepatocyte
Nuclear Factor-4a is highly dependent on its physical
interaction with PGC-1 and SRC3 (41). Thus, we hy-
pothesize that ADA3 utilizes a similar binding pocket as
p160 co-activators in regulating RAR signaling. While
ADA3 and p160 co-activators share the same binding
property to RARa, it is conceivable that these two
co-activators may compete with each other if present at
the same time. It will be of special interest to know
whether there is speciﬁc physiological condition(s) that
governs a potential binding switch from p160 to ADA3,
or vice versa.
With the help of molecular modeling, we have created a
structural model of the hADA3 NR box 4 peptide/
hRARa LBD complex (Figure 7). This thermodynamic-
ally stable complex is reminiscent of the TRAP220 NR
box 2/hRARb LBD complex that was previously solved
by X-ray crystallography (31). Similar to other
co-activator complex, the primary interaction comes
from the three core hydrophobic residues of the LxxLL
motif, whose side chains interpolate deeply into the
co-activator pocket. Many hydrophobic contacts are
formed with residues from RARa LBD helices 3, 4, 5
and 12 (Table 1). Nearly all of these residues are conserved
amongst diﬀerent NRs and required for binding with
other co-activators (28,29,36,38,42,43). In agreement
with this model, our data show that the three predicted
contacting residues in H12, Leu409, Glu412 and Met413
are all required for ADA3 interaction (Figure 3).
Similarly, Val240 in helix 3, Phe249 in helix 4 and
Leu261 in helix 5 are also important for ADA3 binding
(data not shown). It is interesting to note that additional
residues within and around H12 are also important for
ADA3 binding. Based on this model, a complex
hydrogen bond network is predicted between the
N-terminal of the NR box 4 peptide and the surrounding
residues on the receptor (Figure 7B). Importantly, two
additional electrostatic interactions between Arg-2 and
Asn416 and Gln-3 and Lys262 may explain the diﬀerential
aﬃnity of the ﬁve LxxLL sequences for their interaction
with RARa. The Leu-2 and Val-3 residues on NR box 1
and 2, respectively, may prevent formation of hydrogen
bond, thus this hydrogen bond network may only occur
with NR boxes 3, 4 and 5.
Taken together, we have provided strong evidence that
support an important role of hADA3 as a transcriptional
co-activator for RARa in mammalian cells. These data
suggest a mechanism through which the mammalian
ADA3 may direct the action of multi-functional
co-activator complexes toward modulating NR signaling.
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